A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Mycophenilic Acid (Mycophenolic Acid)

Antimetabolite Immunosuppressant class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2022-02-21
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.127/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.175
Across all dosage forms in distribution.
Highest NADAC
$0.222
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Mycophenilic Acid used for?

Mycophenilic Acid is a Antimetabolite Immunosuppressant medication tracked in Medicare Part D.

Is there a generic for Mycophenilic Acid?

No. Mycophenilic Acid is brand-only with no generic equivalents currently in market.

How much does my plan pay for Mycophenilic Acid?

Across 329 Part D plans, Mycophenilic Acid averages $0.175/unit (NADAC). Lowest available: $0.127/unit. Highest in distribution: $0.222/unit.

Is Mycophenilic Acid on the FDA shortage list?

No. Mycophenilic Acid is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antimetabolite Immunosuppressant1 alternative in D1
01
Mycophenolic Acid
Brand: Myfortic
$0.127Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.